Cystic Fibrosis
Conditions
Keywords
mannitol, cystic fibrosis, mucolytic, mucoactive
Brief summary
Cystic fibrosis is the most frequent lethal genetic disease of childhood. Causes disruption of glandular function of the pancreas, intestine, liver, lungs (causing chronic lung infection with emphysema), sweat glands and reproductive organs. We know that many CF patients die of lung failure, brought about in part by repeated lung infections caused by thick, sticky mucus that cannot be readily cleared from the lung. Inhaled mannitol is an osmotic agent that has been investigated in a number of small studies that have examined mucociliary clearance, quality of life and lung function in CF and bronchiectasis. The promising results of these studies warrant futher investigation. The aim of this study is to assess the safety and efficacy of inhaled mannitol when administered twice a day over two weeks in CF.
Interventions
DRUGInhaled mannitol
Sponsors
Syntara
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
8 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Confirmed diagnosis of cystic fibrosis (sweat test/genotype) 2. Aged 8 years or older 3. Have FEV1 between 40% and 80% of predicted for height, age and gender OR a decrease in FEV1 of 20% or more than that recorded 6-12 months previously. 4. As determined by the investigator, are capable and willing to * Use the study diary as required for this protocol * Able to perform all of the techniques necessary to measure lung function * Able to administer the dry powder mannitol 5. Are capable of and have given informed consent 6. Clinically stable at study entry
Exclusion criteria
1. Investigators, site personnel directly affiliated with this study, and their immediate families. 2. Subjects under the age of 8 years. 3. Subjects with currently active asthma 4. Subjects using hypertonic saline treatment in the last 2 weeks 5. Considered terminally ill or listed for transplantation 6. Requiring home oxygen or assisted ventilation 7. Colonisation with Burkholderia cepacia 8. Significant episode of hemoptysis (\>60 mls) in the previous 12 months 9. Myocardial Infarction in the six months prior to enrolment. 10. Cerebral Vascular Accident in the six months prior to enrolment. 11. Ocular surgery in the three months prior to enrolment. 12. Abdominal surgery in the three months prior to enrolment. 13. Subjects who are breast feeding or pregnant. 14. Female subjects of reproductive capability, not using a reliable form of contraception 15. Inability to obtain informed consent from the subject or subject's authorised representative. 16. Subjects who have participated in another investigative drug study parallel to, or within 4 weeks of study entry. 17. Known intolerance to mannitol or beta2 agonists. 18. Uncontrolled hypertension - systolic BP \> 160 and or diastoli
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FEV1 | — |
Secondary
| Measure | Time frame |
|---|---|
| Other measures of lung function | — |
| Quality of life | — |
| Sputum microbiology | — |
| Sputum rheology | — |
| Safety | — |
Countries
Australia, New Zealand
Outcome results
None listed